Agilusedge Cgp Rapid

What is Agilus EDGE CGP Rapid test?

Agilus EDGE CGP Rapid is a comprehensive genomic profiling (CGP) assay for solid tumors that analyzes 500+ clinically relevant cancer genes and key genomic signatures, with an accelerated turnaround time of 4 working days from sample receipt—dramatically faster than traditional multi-gene NGS workflows that often take several weeks. It is designed to deliver an integrated, clinician-ready report that maps detected alterations to targeted therapies, immunotherapies, and relevant clinical trials, helping enable earlier, evidence-based treatment decisions when time is critical.

Why consider Agilus EDGE CGP Rapid test?

• Simultaneous Analysis of a broad range of relevant and emerging biomarkers in one test to help maximize insights into the underlying oncogenic drivers in a timely manner
• Analysis of the main classes of genomic alterations, including SNVs, insertions and deletions (indels), CNVs and Fusions across pan cancer samples
• Assessments of genomic signatures such as HRD, TMB and MSI

Who should get this Agilus EDGE CGP Rapid test?

• Patients with newly diagnosed advanced or metastatic solid tumors where broad, upfront genomic profiling can uncover multiple actionable targets (e.g., lung, colorectal, breast, prostate, cholangiocarcinoma, sarcomas, and other rare cancers).
• Patients with progression on standard therapies or with limited tissue, where a single, comprehensive test maximizes the chance of finding actionable alterations and clinical trial options.

More Information about Agilus EDGE CGP Rapid test

OTHER NAMES: Agilus EDGE Comprehensive Genomic Profile (CGP), Agilus EDGE CGP (500+ gene pan-cancer profile), Oncomine comprehensive panel, Cancer 500 gene panel, 500+ gene panel for cancer, Comprehensive Genomic Profile

Solid tumors are cancers that arise from epithelial, mesenchymal, neuroendocrine, or other non-hematologic tissues and form a mass or “solid” lesion, as opposed to blood cancers like leukemias that circulate without forming discrete masses. They include carcinomas (e.g., lung, breast, colorectal), sarcomas (e.g., soft tissue, bone), neuroendocrine tumors, central nervous system tumors, and many rarer entities.